🚀Enjoy a 7-Day Free Trial Until Jul 20, 2024!

NR

Neurosense Therapeutics LtdNASDAQ NRSN Stock Report

Price

Market cap $B

Exchange

XNAS - Nasdaq

FAIR VALUE

Is NRSN undervalued compared to its fair value?

The fair value of NRSN stock is hidden USD. Relative to the market price of 1.01 USD Neurosense Therapeutics Ltd is hidden.

Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company. The firm is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerativ...[More about valuation]

Neurosense Therapeutics Fair Value

hidden
UNLOCK
What is fair value?

Market cap:

0.019 $B

Price:

1.01 USD

Fair value:

hidden

Max value:

hidden

Min value:

hidden

P/E:

hidden

EPS:

FINANCIALS

Neurosense Therapeutics financial for reporting period

Income Statement


Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A

Balance Sheet

Financial Position Analysis

Cash Flow Statement

-N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A

Neurosense Therapeutics fundamental analysis for trailing twelve months (TTM)

Profitability score


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Solvency Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Efficiency Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Dupont Analysis

Stability Indicators

STOCK ANALYSIS

Is NRSN attractive for investment based on fundamental analysis?

NRSN stock rating is hidden. Neurosense Therapeutics is a hidden by Eyestock methodology.

Get NRSN Stock Rating
to complete you analysis
UNLOCK
Learn more about quality score?

Net Profit Margin:

Gross Margin:

CFO / Debt ratio:

hidden

Current ratio:

Debt / Equity ratio:

ROE:

ROIC:

hidden

Stability Ratio (2y):

hidden

Stability Ratio (5y):

hidden

Earnings quality:

hidden

NRSN analysis by AI

Eyebot AI analysis

We carefully consider 10 indicators for NRSN to calculate the final rating score. Use AI leverage to quickly get the main conclusions before diving into the details

Neurosense Therapeutics Ltd competitors

AB

ABBV

Abbvie Inc

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Ill...

Discover

AM

AMGN

Amgen Inc

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. The Company...

Discover

VR

VRTX

Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs fo...

Discover

Neurosense Therapeutics Ltd dividends

NRSN dividend metrics

Payout ratio
Dividend yield
Annual dividend
Dividend streak
Average dividend yield over 3 years
Average dividend yield over 5 years

Dividend per share

By years
By payments
1y
3y
5y
All time
This ticker has no dividend history

About NRSN stock

About the company Neurosense Therapeutics Ltd

Market cap $B

0.019

Dividend yield

Shares outstanding

11.67398 B

Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company. The firm is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The firm's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease

NRSN profile

  • Ticker

    NRSN

  • Country

    Israel

  • Exchange

    XNAS - Nasdaq

  • Report currency

    USD - US dollar

  • IPO date

    09 December 2021

  • Sector

    Healthсare

  • Industry

    Biotechnology

  • Employees

    11

  • City

    Herzliya

  • Address

    11 Hamenofim St., Building B

  • Cusip

    M74240108